Back to Search Start Over

Biomarqueurs inflammatoires et immunologiques de réponse à la radiothérapie

Authors :
J.P. Nesseler
Philippe Nickers
Dörthe Schaue
William H. McBride
Source :
Cancer/Radiothérapie. 22:180-192
Publication Year :
2018
Publisher :
Elsevier BV, 2018.

Abstract

In radiotherapy, the treatment is adapted to each individual to protect healthy tissues but delivers most of time a standard dose according to the tumor histology and site. The only biomarkers studied to individualize the treatment are the HPV status with radiation dose de-escalation strategies, and tumor hypoxia with dose escalation to hypoxic subvolumes using FMISO- or FAZA-PET imaging. In the last decades, evidence has grown about the contribution of the immune system to radiation tumor response. Many preclinical studies have identified some of the mechanisms involved. In this context, we have realised a systematic review to highlight potential inflammatory and immune biomarkers of radiotherapy response. Some are inside the tumor microenvironment, as lymphocyte infiltration or PD-L1 expression, others are circulating biomarkers, including different types of hematological cells, cytokines and chemokines.

Details

ISSN :
12783218
Volume :
22
Database :
OpenAIRE
Journal :
Cancer/Radiothérapie
Accession number :
edsair.doi.dedup.....9c230839cdef6c48f101ffa6c8542b57
Full Text :
https://doi.org/10.1016/j.canrad.2017.09.007